Cascadian Therapeutics' P2P Acquisition

Cascadian Therapeutics raised a round of funding on March 09, 2018. Investors include Seattle Genetics.

Cascadian Therapeutics, fka Oncothyreon, is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer.…

Articles about Cascadian Therapeutics' P2P Acquisition: